Psychedelics Billionaire Steve Cohen’s Point 72 hedge fund takes 8.1% stake in Cybin It now has 19 million shares of the psychedelic drug developer, the firm's first investment in a public entity of this variety Rowan DunneSeptember 19, 2023
Psychedelics Cybin inks agreement to acquire DMT drug developer Small Pharma The companies say they will have the most substantial dataset on the DMT molecule in the industry and largest IP portfolio Rowan DunneAugust 28, 2023
Canada Cybin acquires license for psychedelic molecules from Mindset Cybin will pay Mindset an initial US$500K and 'development milestone payments' that could potentially total US$9.5M afterward Rowan DunneSeptember 27, 2022
Canada Cybin administers psychedelic analogue to patients with major depression First novel psilocybin compound to commence clinical development marks 'tremendous milestone' for biotechnology company Rowan DunneAugust 30, 2022
Cannabis Cybin receives Schedule I DEA license for CYB003 trial New license is the final required step before administering doses to study participants Rowan DunneAugust 17, 2022
Alternative Energy Cybin receives FDA approval for new in-human clinical trial Patient enlistment for new study to treat Major Depressive Disorder set to begin promptly Rowan DunneJune 28, 2022